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The aim of this study was to investigate themechanisms responsible for resistance to antimicrobials in a collection of enterobacterial
isolates recovered from two hospitals in Saudi Arabia. A total of six strains isolated from different patients showing high resistance
to carbapenems was recovered in 2015 from two different hospitals, with four being Klebsiella pneumoniae and two Enterobacter
cloacae. All isolates except one K. pneumoniae were resistant to tigecycline, but only one K. pneumoniae was resistant to colistin.
All produced a carbapenemase according to the Carba NP test, and all were positive for the EDTA-disk synergy test for detection
of MBL. Using PCR followed by sequencing, the four K. pneumoniae isolates produced the carbapenemase NDM-1, while the two
E. cloacae isolates produced the carbapenemase VIM-1. Genotyping analysis by Multilocus Sequence Typing (MLST) showed that
three out of the four K. pneumoniae isolates were clonally related. They had been recovered from the same hospital and belonged
to Sequence Type (ST) ST152. In contrast, the fourth K. pneumoniae isolate belonged to ST572. Noticeably, the NDM-1-producing
K. pneumoniae additionally produced an extended-spectrum ß-lactamase (ESBL) of the CTX-M type, together with OXA-1 and
TEM-1. Surprisingly, the three clonally related isolates produced different CTX-M variants, namely, CTX-M-3, CTX-M-57, and
CTX-M-82, and coproduced QnrB, which confers quinolone resistance, and the 16S rRNA methylase RmtC, which confers high
resistance to all aminoglycosides.The AAC(6󸀠)-Ib acetyltransferase was detected in both K. pneumoniae and E. cloacae. Mating-out
assays using Escherichia coli as recipient were successful for all isolates.The 𝑏𝑙𝑎NDM-1 gene was always identified on a 70-kb plasmid,
whereas the 𝑏𝑙𝑎VIM-1 gene was located on either a 60-kb or a 150-kb plasmid the two E. cloacae isolates, respectively. To the best of
our knowledge, this is the first report of the coexistence of an MBL (NDM-1), an ESBL (CTX-M), a 16S rRNA methylase (RmtC),
an acetyltransferase (AAC[6󸀠]-Ib), and a quinolone resistance enzyme (QnrB) in K. pneumoniae isolates recovered from different
patients during an outbreak in a Saudi Arabian hospital.
1. Introduction
Metallo-𝛽-lactamases (MBLs) are enzymes that hydrolyze
most 𝛽-lactams including carbapenems, the most potent
𝛽-lactams. Therefore, resistance mediated by MBLs is
considered the most serious mechanism for inactivating
𝛽-lactams [1]. Of the clinically relevant MBLs, NDM, VIM,
and IMP are the most common worldwide [2, 3]. Klebsiella
pneumoniae and Enterobacter cloacae are Enterobacteriaceae
that are leading causes of nosocomial infections and can
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Table 1: Isolate case histories and characteristics.
Isolate Hospital/City Patient age (years) Patient sex Specimen source Diagnosis
KP-Q1 A/ Al-Gouf 65 Male Blood Septic encephalopathy
KP-Q2 A/ Al-Gouf 95 Male Sputum Pulmonary fibrosis
KP-Q3 A/ Al-Gouf 70 Female Wound Gangrene of diabetic foot with sepsis
KP-Q4 B/ Riyadh 50 Male Wound Urogenital infection
EN.C.Q5 B/ Riyadh 64 Female Blood ND
EN.C.Q6 B/ Riyadh 78 Male Blood Cystic fibrosis
KP: Klebsiella pneumoniae
EN.C: Enterobacter cloacae
ND: Not determined
frequently acquire antibiotic resistance [4]. K. pneumoniae
and E. cloacae can acquire resistance to third-generation
cephalosporins through plasmid-mediated AmpC 𝛽-lac-
tamases, such as CMY, FOX, ACC, LAT, MIR, MOX, DHA,
and ACT [5], as well as extended-spectrum 𝛽-lactamases
(ESBL), such as CTX-M, TEM-, and SHV-derivatives.
Acquisition of carbapenem resistance in those bacterial
species may be related to several carbapenem-hydrolyzing
ß-lactamases, such as KPC, NDM, VIM, and OXA-48 [6].
Several mechanismsmay confer aminoglycoside resistance to
Enterobacteriaceae, including production of aminoglycoside-
modifying enzymes, such as aminoglycoside acetyltrans-
ferases (AACs), phosphotransferases (APHs), and adeny-
lyltransferases (ANTs), but also target modifications by
mutations in ribosomal proteins, or 16S rRNA methylation
through the action of 16S rRNAmethylases [7]. AACs are the
most common aminoglycoside-modifying enzymes and are
subdivided into four groups [AAC(1), AAC(2󸀠), AAC(3), and
AAC(6󸀠)]. AAC(6󸀠) comprises the most common enzymes
in Gram-negative bacteria and can be subdivided into two
groups: AAC(6󸀠)-I and AAC(6󸀠)-II [8, 9]. Enterobacteriaceae
may also produce 16S rRNA methylases, including ArmA,
RmtA to RmtH, and NpmA, which confer resistance to
aminoglycosides [10].Theplasmid-mediated quinolone resis-
tance genes qnrA, qnrB, qnrC, qnrD, qnrS, and qnrVC code
for Qnr proteins that protect DNA gyrase and topoisomerase
IV from the action of quinolones, conferring quinolone
resistance [11]. In this study, we aimed to investigate the
mechanisms responsible for carbapenem resistance in a col-
lection of enterobacterial isolates recovered from two hospi-
tals in Saudi Arabia. Carbapenemase-producing isolates were
also further investigated for additional antibiotic resistance
traits.
2. Materials and Methods
2.1. Bacterial Isolates. FourK. pneumoniae and two E. cloacae
isolates from twohospitals inRiyadh, the capital of SaudiAra-
bia andAl-Gouf, the north region of SaudiArabiawere highly
resistant to carbapenems. Three K. pneumoniae isolates (KP-
Q1, KP-Q2, and KP-Q3) were obtained from hospital A while
a singleK. pneumoniae (KP-Q4) and two E. cloacae (EN.C.Q5
and EN.C.Q6) isolates were collected from hospital B in 2015
(Table 1). Isolates were identified in the clinical laboratory
using the VITEK 2 system (bioMe´rieux, Marcy l’Etoile,
France) and confirmed by conventional morphological and
biochemical tests.
2.2. Antimicrobial Susceptibility Testing and Phenotypic
Carbapenemase Detection. Etest strips (bioMe´rieux,Marcy
l’Etoile, France) and disk diffusion methods (Oxoid, UK)
were used to determine susceptibility to antimicrobials
other than colistin, whose susceptibility was tested using a
microbroth dilution method. The guidelines of the Clinical
Laboratory Standards Institute (CLSI, 2016) [12] were used
to interpret MICs except for tigecycline and colistin, whose
data were interpreted according to the 2019 guidelines of the
EuropeanCommittee onAntimicrobial Susceptibility Testing
(EUCAST) [13]. The Carba NP test [14] was carried out
to detect carbapenemase activity. Production of MBL was
screened by an EDTA-disk synergy test [15].
2.3. PCR Ampliﬁcation of Resistance Genes. Carbapenem-
resistant enterobacterial isolates were collected from 200 𝜇L
volumes of overnight Luria Bertani broth (Thermo Fischer
Scientific, Waltham, MA, USA) cultures and resuspended in
equal volumes of sterile distilled water, heated at 99∘C for
10 min on a heating block, and then centrifuged at 15,000
rpm for two minutes. The supernatant, which contained
released DNA, was used directly in PCR amplification of
the resistance genes on a Techne Flexigene Thermocycler
(Techne, Duxford, Cambridge, UK). Positive and negative
controls were included in all PCR runs. All PCR amplicons
were electrophoresed on 0.8% agarose gels containing 0.5
mg/L ethidium bromide and then analyzed under UV light
(Pharmacia LKB; Biotechnology AB, Gothenburg, Sweden)
and photographed using a documentation system.
The multiplex PCR protocol described by Dallenne et al.
[16] was used to amplify four types of class A 𝛽-lactamase
genes (TEM, SHV, five CTX-M families, and an OXA-1-
like). Multiplex PCR was used to seek plasmid-mediated
AmpC𝛽-lactamase genes, including ACC, FOX,MOX, CMY,
LAT, and MIR, as previously described [17] using six pairs
of primers. Ten carbapenemase genes, including IMP, VIM,
NDM, SIM, SPM, GIM, AIM, DIM, OXA-48, and KPC, were
tested via three multiplex reactions according to the method
of Poirel et al. [18]. Moreover, the isolates were screened by
multiplex PCR for qnrA, qnrB, and qnrS plasmid-mediated
quinolone resistance genes [19], whereas a simplex PCR
was performed to detect AAC(6󸀠)-Ib [7]. Additionally, six
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Table 2: Antimicrobial resistance profile of six resistant Klebsiella pneumoniae and Enterobacter cloacae isolates.
Antibiotics MIC (mg/L)
KP-Q1 KP-Q2 KP-Q3 KP-Q4 EN.C.Q5 EN.C.Q6
Amoxicillin >256 >256 >256 >256 >256 >256
Piperacillin >256 >256 >256 >256 >256 >256
Ticarcillin >256 >256 >256 >256 >256 >256
Cefoperazone >256 >256 >256 >256 >256 >256
Cefotaxime >256 >256 >256 >256 >256 >256
Ceftazidime >256 >256 >256 >256 >256 >256
Cefepime >256 >256 >256 >256 >256 >256
Aztreonam >256 >256 >256 >256 >256 >256
Cefoxitin >256 >256 >256 >256 >256 >256
Cefotetan >256 >256 >256 >256 >256 >256
Imipenem >256 >256 >256 >256 >256 >256
Meropenem >32 >32 >32 >32 >32 >32
Doripenem >32 >32 >32 >32 >32 >32
Amikacin >256 >256 >256 >256 24 (S) >256
Gentamicin >256 >256 >256 >256 64 >256
Nalidixic acid >256 >256 >256 >256 >256 >256
Ciprofloxacin >32 >32 >32 >32 2 (S) 8
Ofloxacin >32 >32 >32 >32 2 (S) 8
Tigecycline 0.75 0.75 0.75 0.19 (S) 2 2
Colistin 0.75 (S) 3 1.5 (S) 2 (S) 0.75 (S) 0.75 (S)
Inhibition zone diameter (mm) by disk diffusion
Sulfamethoxazole/trimethoprim 23.75 / 1.25 𝜇g 6 6 6 6 6 6
Tetracycline 30 𝜇g 6 6 8 15 (S) 6 12 (I)
Chloramphenicol 30 𝜇g 22 (S) 23 (S) 21 (S) 16 (S) 6 6
KP: Klebsiella pneumoniae, EN.C: Enterobacter cloacae
S: susceptible, I: intermediate
Disk diameter is 6 mm
MIC: Minimum Inhibitory Concentration
Resistance interpretation for all antimicrobials unless labeled S or I
Interpretation according to CLSI guidelines (2016) except for tigecycline and colistin, which were interpreted according to EUCAST guidelines (2019).
16S rRNA methylase genes were tested using two multiplex
reactions, with the first detecting armA, rmtB, and npmA
and the second rmtA, rmtC, and rmtD according to the
previously published method [20]. The PCR products were
sequenced and analyzed using the NCBI database with the
BLAST program (http://www.ncbi.nlm.nih.gov).
2.4. Multilocus Sequence Typing (MLST) Analysis. Clonal re-
latedness was determined by MLST according to the Pasteur
Institute scheme for the K. pneumoniae isolates (https://
bigsdb.pasteur.fr/klebsiella/klebsiella.html) and according to
the PubMLST protocol and database for theE. cloacae isolates
(https://pubmlst.org/ecloacae/).
2.5. Plasmid Extraction and Conjugation Experiment. A plas-
mid extraction protocol [21] was used to investigate the
presence of plasmids in all isolates and was followed by direct
agarose gel electrophoresis of extracted DNA. Bac-tracker
(Epicentre, Madison, WI, USA) was used as a plasmid size
marker.
Transfer of imipenem resistance genes by conjugation
from our isolates as donors was attempted by filter mating
[22] with Escherichia coli J53 sodium azide resistant as the
recipient strain. The initial donor/recipient ratio was 1:5
or 1:10. Transconjugants were selected on MacConkey agar
containing sodium azide (100 mg/L) and ceftazidime (4
mg/L).
3. Results
MICs of different antibiotics for the six carbapenem-resistant
K. pneumoniae and E. cloacae isolates are shown in Table 2.
All isolates were highly resistant to all tested 𝛽-lactams.
They all remained susceptible to tigecycline (MIC ≤ 2 mg/L)
according to the EUCAST 2016 breakpoint, although the
cut-off tigecycline in EUCAST 2019 guidelines is 0.5 mg/L.
Consequently, all our isolates, except one K. pneumonia,
were resistant to tigecycline using the new EUCAST defi-
nition. A single K. pneumoniae isolate (KP-Q2) was resis-
tant to colistin according to the EUCAST definition (MIC
> 2 mg/L is considered resistant). Moreover, the four K.
pneumoniae isolates were determined to be susceptible to
chloramphenicol with inhibition zone diameters > 12 mm
according to the 2016 CLSI guidelines, whereas the two
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E. cloacae isolates were resistant to this compound. Resis-
tance to sulfamethoxazole/trimethoprim was also observed
in all isolates. Four isolates (three K. pneumoniae and a
single E. cloacae) were resistant to tetracycline. Resistance
profiles of aminoglycosides (amikacin and gentamicin) and
quinolones/fluoroquinolones (nalidixic acid, ciprofloxacin,
and ofloxacin) are presented in Table 2.
All isolates exhibited a carbapenemase activity as detected
by the Carba NP test. MBL production was detected by
EDTA-disk synergy tests in all isolates.This was confirmed by
PCR, with the 𝑏𝑙𝑎NDM-1 carbapenemase gene being amplified
in the four K. pneumoniae isolates and the 𝑏𝑙𝑎VIM-1 gene
being amplified in the two E. cloacae isolates (Table 3). No
additional carbapenemase gene was identified in those six
isolates.
Additionally, three K. pneumoniae isolates harbored a 16S
rRNA methylase encoding gene, rmtC, and the quinolone
resistance gene, qnrB. Moreover, a single E. cloacae iso-
late harbored the plasmid-mediated AmpC-encoding genes,
𝑏𝑙𝑎CMY-4. Additionally, all isolates were found to harbor CTX-
M-ESBL-encoding genes. All K. pneumoniae isolates were
found to harbor OXA-1 broad spectrum beta-lactamases
(BSBL). TEM-1-BSBL was found in all isolates except E. cloa-
cae isolate EN.C.Q6.The aminoglycoside-modifying enzyme
AAC(6󸀠)-Ib was found in all isolates except E. cloacae isolate
EN.C.Q5 (Table 3).
Transfer of imipenem resistance from all isolates to E.
coli J53 was attempted by filter mating. The conjugation
experiment demonstrated conjugative transfer of 𝑏𝑙𝑎NDM-1
fromK. pneumoniae and 𝑏𝑙𝑎VIM-1 from E. cloacae toE. coli J53,
confirming carriage of both genes on transferable plasmids.
In K. pneumoniae, a single 70-kb plasmid was identified in
all four isolates, onto which the 𝑏𝑙𝑎NDM-1 gene was located.
On the other hand, the 𝑏𝑙𝑎VIM-1 gene was located on a 60-kb
plasmid in a single E. cloacae isolate and on a 150-kb plasmid
in the other isolate (Figure 1).
MLST genotyping revealed that three K. pneumoniae
isolates, which had actually been recovered from same hos-
pital, belonged to ST152. The fourth K. pneumoniae isolate
belonged to ST572 and had been recovered from the other
hospital.
4. Discussion
The overuse of carbapenems during the last decade has
led to increasing levels of bacterial resistance toward these
potent 𝛽-lactams. Enterobacterial isolates have shown high
carbapenem resistance rates worldwide, making alternative
antibiotics, such as colistin and tigecycline, urgently needed.
In the current study, we investigated by using phenotypic and
genotypic methods six carbapenem-resistant enterobacterial
isolates for their multiresistance determinants. In a recent
study from Saudi Arabia [23], tigecycline resistance was not
detected among 31 Enterobacteriaceae clinical isolates (21 K.
pneumoniae and 10 E. coli) whereas colistin resistance was
seen in 10% (one isolate) and 4.8% (one isolate) of their E. coli
andK. pneumonia isolates, respectively. Similarly, colistin and
tigecycline susceptibility were 100 and 87.5%, respectively,
in 16 extensively drug-resistant K. pneumoniae strains from
1 1098765432 11 1312 14 15
Figure 1: Electrophoretic profile of the plasmid DNA extracts
from the strains and their transconjugants to confirm the results.
1. Ladder 1kb (10kb,8kb,6kb,5kb,4kb,3kb,2kb,1.5kb,1kb). 2. Ladder
control strain 50192 (154kb, 66kb, 48kb, 7.8kb). 3. KP1 strain (70kb).
4. KP1 Transconjugant strains (70kb). 5. KP 2 (70kb). 6. KP2
Transconjugant strains (70kb). 7. KP 3 (70kb). 8. KP3 Transconju-
gant strains (70 kb). 9. KP 4 strains (70kb). 10. KP 4 Transconjugant
strain 4 (70 kb). 11. EN.C 5 strains (60 kb). 12. EN.C 5Transconjugant
strain (60kb). 13. EN.C 6 strain (150kb). 14. EN.C6 Transconjugant
strains (150kb). 15. Ladder control strain 50192 (154kb, 66kb, 48kb,
7.8kb).
Saudi Arabia [24]. According to several reports [25–27],
colistin and tigecycline remain the most effective antibiotics
against carbapenem-resistant Gram-negative pathogens.
Interestingly, the 2019 EUCAST guidelines (http://www
.eucast.org/fileadmin/src/media/PDFs/EUCAST files/Break-
point tables/v 9.0 Breakpoint Tables.pdf) [13] changed the
tigecycline resistance breakpoint to MIC > 0.5 mg/L.
According to this new definition, all our isolates except
one K. pneumoniae isolate would be considered resistant,
suggesting an increasing challenge to public health. In the
current study, resistance to colistin is not determined in our
isolates, except one K. pneumonia isolate which has low-level
colistin resistance (MIC 3 mg/L).
Twomembers ofMBLswere detected among our isolates,
namely, NDM-1-producingK. pneumoniae isolates and VIM-
1-producing E. cloacae isolates. Although OXA-48 is com-
monly identified amongK. pneumoniae isolates in some parts
of Saudi Arabia [28–30], this resistance determinant was not
detected in the present study. Moreover, a multicenter study
in Saudi Arabia, Memish et al. [28], reported that OXA-48
and NDM-1 are the dominant carbapenemases among 124
Enterobacteriaceae (E. coli, Klebsiella spp., and Enterobacter
spp.) isolated from 12 cities across the Kingdom of Saudi
Arabia with low incidence of VIM and complete absence of
KPC and IMP.
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The coexistence of 16S rRNA methylase genes with 𝛽-
lactamase genes was previously observed in Saudi Arabia.
ESBLs were reported along with armA, rmtB, rmtC, and
npmA in Enterobacteriaceae [31]. OXA-48 and NDM were
detected along with armA and rmtB in K. pneumoniae
[24]. The current study also revealed that the three clonally
related K. pneumoniae isolates harbored the rmtC gene along
with 𝑏𝑙𝑎NDM-1. In addition, the plasmid mediated AmpC 𝛽-
lactamase variant, CMY-4, was determined in our study in
one E. cloacae which coproduces VIM-1 as well.This finding
is the first report describing CMY carriage by a clinical E.
cloacae isolate from Saudi Arabia.
The gene encoding the aminoglycoside-modifying
enzyme AAC(6󸀠)-Ib was detected in all but one isolates
in our study. This enzyme was previously detected among
extensively drug-resistant K. pneumonia isolates in Saudi
Arabia [24]. Furthermore, the gene encoding the quinolone
resistance protein QnrB was detected in the K. pneumoniae
isolates from our study, in accordance with previous reports
from Saudi Arabia [23, 24].
Noteworthy, strain EN.C.Q5 of our E. cloacae isolates
was resistant to gentamicin although it did not have any of
aminoglycoside resistance determinant examined (16S rRNA
methylase: armA, rmtA, rmtB, rmtC, rmtD, and npmA, or
acetyltransferase AAC(6󸀠)-Ib), suggesting other resistance
mechanism involved. Similarly, K. pneumonia strain KP-Q4
and E. cloacae strain EN.C.Q6 were resistant to ciprofloxacin
and ofloxacin without qnrA, qnrB, and qnrS plasmid medi-
ated quinolone resistance genes. Quinolone resistance in
these isolates may be due to other plasmid mediated genes
or mutations in quinolone resistance–determining regions
of DNA gyrase (gyrA and gyrB) or DNA topoisomerase IV
(parC and parE) [32].
5. Conclusions
Our study reports on a series of threatening resistance
determinants responsible for the multidrug resistance pat-
tern observed among clinical isolates. The identification of
MBL-encoding genes (𝑏𝑙𝑎VIM in E. cloacae and 𝑏𝑙𝑎NDM in
K. pneumoniae) being identified onto conjugative plasmids
raises concerns about the real extend of diffusion of those
resistance genes in Saudi Arabia. Cooccurrence of multiple
resistance determinants in clonally related K. pneumoniae
isolates highlights the importance of controlling the dissem-
ination of such isolates by early detection in hospital set-
tings.
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